FDA On Drug Pricing: Incremental Steps, But No Full-Frontal Assault

US agency will continue to avoid ‘big bold’ actions on drug pricing under the Trump Administration, industry representatives and attorneys predict, adding that easing restrictions on manufacturer communications to payers and advocating for biosimilars would help in pricing debate.